These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21503406)

  • 1. Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae.
    Nogueira Kda S; Daur AV; Reason IT; Gales AC; Costa LM
    Braz J Infect Dis; 2011; 15(2):167-9. PubMed ID: 21503406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.
    Smith KP; Brennan-Krohn T; Weir S; Kirby JE
    J Clin Microbiol; 2017 Feb; 55(2):470-478. PubMed ID: 27903600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam.
    Bert F; Bialek-Davenet S; Leflon-Guibout V; Noussair L; Nicolas-Chanoine MH
    Med Mal Infect; 2014 Feb; 44(2):76-8. PubMed ID: 24525113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.
    Szabó D; Bonomo RA; Silveira F; Pasculle AW; Baxter C; Linden PK; Hujer AM; Hujer KM; Deeley K; Paterson DL
    J Clin Microbiol; 2005 Oct; 43(10):5058-64. PubMed ID: 16207962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
    Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
    Pottumarthy S; Deshpande LM; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.
    Drieux L; Brossier F; Sougakoff W; Jarlier V
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():90-103. PubMed ID: 18154532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
    Hombach M; Mouttet B; Bloemberg GV
    J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of extended-spectrum beta-lactamases in Enterobacter cloacae in Taiwan and comparison of 3 phenotypic confirmatory methods for detecting extended-spectrum beta-lactamase production.
    Yang JL; Wang JT; Lauderdale TL; Chang SC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):310-6. PubMed ID: 19949754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.
    Rhodes NJ; Richardson CL; Heraty R; Liu J; Malczynski M; Qi C; Scheetz MH
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3757-61. PubMed ID: 24752253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
    Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT; Heil EL; Leekha S; Fowler RC; Hanson ND; Majumdar A; Johnson JK
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
    Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
    Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
    Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
    Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.